{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:23:55Z","timestamp":1781540635402,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV plus chemotherapy in patients with LAGC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty resectable patients with LAGC who received BEV plus docetaxel\/cisplatin\/capecitabine (DCC) chemotherapy for 3 cycles with 21 days as one cycle as neoadjuvant regimen were involved. Besides, their treatment response, survival profiles, and adverse events were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, two (10.0%), 9 (45.0%), 8 (40.0%), and 1 (5.0%) patients achieved complete remission, partial remission, stable disease, and progressive disease (PD) according to imaging evaluation, which resulted in 55.0% of objective response rate and 95.0% of disease control rate, respectively. Moreover, the number of patients with pathological response grades 1, 2, and 3 was 8 (40.0%), 8 (40.0%), and 3 (15.0%); while 1 (5.0%) patient did not receive surgery due to PD, thus the data of this patient was not assessable. Meanwhile, 18 (90.0%) patients achieved R0 resection. Regarding survival profile, the median disease-free survival or overall survival were both not reached. The 1-year, 2-, and 3-year disease-free survival rates were 88.8, 80.7, and 67.3%. Meanwhile, the 1-, 2-, and 3-year overall survival rates were 100.0%, 75.8%, and 75.8%, respectively. Additionally, the main adverse events were anemia (90.0%), alopecia (90.0%), leukopenia (70.0%), and anorexia (65.0%). Indeed, most adverse events were of grade 1 or 2 and were manageable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Neoadjuvant BEV plus DCC chemotherapy presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.842828","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T06:08:21Z","timestamp":1652249301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Neoadjuvant Bevacizumab Plus Docetaxel\/Cisplatin\/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Deguo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","article-title":"Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13304-018-0543-3","article-title":"Progress in gastric cancer","volume":"70","author":"Strong","year":"2018","journal-title":"Updates Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2017.4000","article-title":"Gastric cancer: Metabolic and metabolomics perspectives (Review)","volume":"51","author":"Xiao","year":"2017","journal-title":"Int J Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40364-021-00340-6","article-title":"Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia","volume":"9","author":"Yang","year":"2021","journal-title":"Biomark Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.31662\/jmaj.2018-0006","article-title":"Update on the treatment of gastric cancer","volume":"1","author":"Hashimoto","year":"2018","journal-title":"JMA J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/MOG.0000000000000577","article-title":"Advances in the treatment of gastric cancer: 2019","volume":"35","author":"Ilson","year":"2019","journal-title":"Curr Opin Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.33314\/jnhrc.v0i0.2055","article-title":"Evidence based surgical approach to locally advanced gastric cancer","volume":"17","author":"Thakur","year":"2019","journal-title":"J Nepal Health Res Counc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijsu.2018.01.008","article-title":"Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials","volume":"51","author":"Coccolini","year":"2018","journal-title":"Int J Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamasurg.2019.3473","article-title":"E JY, Wang Y, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial","volume":"154","author":"Li","year":"2019","journal-title":"JAMA Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0215970","DOI":"10.1371\/journal.pone.0215970","article-title":"Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling","volume":"14","author":"Martin-Romano","year":"2019","journal-title":"PLoS ONE."},{"key":"B12","article-title":"Comparative efficacy of levopraziquantel and praziquantel in the treatment of schistosoma japonicum infection","author":"Wang","year":"1987","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.21037\/atm-20-3986","article-title":"Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection?","volume":"8","author":"Ma","year":"2020","journal-title":"Ann Transl Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1879","DOI":"10.1634\/theoncologist.2020-0642","article-title":"Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer","volume":"25","author":"Barzi","year":"2020","journal-title":"Oncologist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1245\/s10434-009-0838-1","article-title":"Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer","volume":"17","author":"Sym","year":"2010","journal-title":"Ann Surg Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13104-018-3137-8","article-title":"Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials","volume":"11","author":"Mawalla","year":"2018","journal-title":"BMC Res Notes."},{"key":"B18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/ijgc-2021-002432","article-title":"Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer","volume":"31","author":"Maene","year":"2021","journal-title":"Int J Gynecol Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/cncr.29800","article-title":"Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)","volume":"122","author":"Ou","year":"2016","journal-title":"Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","year":"2011","journal-title":"Gastric Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4143\/crt.2017.005","article-title":"Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis","volume":"50","author":"Kim","year":"2018","journal-title":"Cancer Res Treat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 11)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/SLA.0000000000001708","article-title":"Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy","volume":"265","author":"Yang","year":"2017","journal-title":"Ann Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4240\/wjgs.v8.i10.706","article-title":"Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer","volume":"8","author":"Dassen","year":"2016","journal-title":"World J Gastrointest Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12032-017-0997-z","article-title":"Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer","volume":"34","author":"Sasaki","year":"2017","journal-title":"Med Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00280-014-2586-6","article-title":"Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study","volume":"74","author":"Ozdemir","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00432-010-0914-8","article-title":"Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression","volume":"137","author":"Xiong","year":"2011","journal-title":"J Cancer Res Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1245\/s10434-019-07299-7","article-title":"Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis","volume":"26","author":"Kano","year":"2019","journal-title":"Ann Surg Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5230\/jgc.2017.17.e3","article-title":"Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis","volume":"17","author":"Ostwal","year":"2017","journal-title":"J Gastric Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: Clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14619","DOI":"10.18632\/oncotarget.23657","article-title":"The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget."},{"key":"B33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10120-015-0580-2","article-title":"Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer","volume":"20","author":"Yoon","year":"2017","journal-title":"Gastric Cancer."}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.842828\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T06:08:24Z","timestamp":1652249304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.842828\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":33,"alternative-id":["10.3389\/fsurg.2022.842828"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.842828","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"842828"}}